WINTON GROUP Ltd Purchases New Holdings in Guardant Health, Inc. $GH

Key Points

• Winton Group acquired 17,130 Guardant Health shares worth approximately $2.57 million in the second quarter. Institutional investors collectively own 92.6% of the company.
• Analysts remain broadly bullish, with 24 Buy ratings and one Strong Buy; the average price target is $188.12, above the stock’s reported $157.38 opening price.
• Guardant Health reported quarterly revenue of $334.98 million, up 44.3% year over year, and an adjusted loss of $0.42 per share that beat expectations. However, insiders sold more than 427,000 shares worth approximately $67.1 million over the past 90 days.

WINTON GROUP Ltd acquired a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 17,130 shares of the company's stock, valued at approximately $2,570,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Orbimed Advisors LLC acquired a new stake in Guardant Health during the 1st quarter worth about $40,199,000. World Investment Advisors acquired a new position in shares of Guardant Health in the 4th quarter valued at about $1,664,000. GSA Capital Partners LLP acquired a new position in shares of Guardant Health in the 2nd quarter valued at about $1,772,000. Ninepoint Partners LP purchased a new stake in shares of Guardant Health in the second quarter worth approximately $2,853,000. Finally, SWS Partners purchased a new stake in shares of Guardant Health in the second quarter worth approximately $11,190,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GH. Piper Sandler lifted their target price on shares of Guardant Health from $135.00 to $193.00 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. Stephens increased their price objective on Guardant Health from $170.00 to $195.00 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Wolfe Research assumed coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $150.00 price objective for the company. BTIG Research restated a "buy" rating and issued a $195.00 target price on shares of Guardant Health in a research note on Wednesday, September 2nd. Finally, Bank of America upped their target price on Guardant Health from $135.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $188.12.

Guardant Health Price Performance

Guardant Health stock opened at $157.38 on Friday. Guardant Health, Inc. has a one year low of $53.40 and a one year high of $176.58. The company's fifty day moving average price is $159.72 and its two-hundred day moving average price is $124.64. The company has a market capitalization of $21.12 billion, a price-to-earnings ratio of -45.09 and a beta of 1.57.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. Guardant Health's quarterly revenue was up 44.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.44) EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.98 earnings per share for the current year.

Insider Activity

In related news, Director Medina Hidalgo sold 1,700 shares of the firm's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total value of $279,208.00. Following the transaction, the director directly owned 4,556 shares in the company, valued at approximately $748,277.44. This trade represents a 27.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ian T. Clark sold 14,180 shares of Guardant Health stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the completion of the transaction, the director owned 2,975 shares in the company, valued at $472,787. This trade represents a 82.66% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 427,024 shares of company stock valued at $67,113,285. Insiders own 5.60% of the company's stock.

Guardant Health Profile

Guardant Health, Inc NASDAQ: GH is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company's products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.